This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cornerstone Therapeutics Reports Fourth Quarter And Full Year 2009 Financial Results





CARY, N.C., March 4 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX) today reported financial results for the three and 12 months ended December 31, 2009.

Highlights

  • Annual net revenues exceeded $100 million for the first time in Company history
  • Fourth quarter net revenues increased $10.0 million, or 48%, to $30.8 million, compared to the fourth quarter of 2008
  • Non-GAAP income from operations(1) for the fourth quarter of $7.4 million based on GAAP income from operations of $3.5 million, compared to non-GAAP income from operations of $730,000 based on a GAAP operating loss of $140,000 in the fourth quarter of 2008  
  • Successful integration of Curosurf® and relaunch of Factive® expanding our base of strategic specialty products
  • Enhanced management team by appointing Andrew K. W. Powell, Esq. as Executive Vice President, General Counsel and Secretary

(1) Non-GAAP income from operations is a non-GAAP financial measure that excludes stock-based compensation, amortization of product rights and acquisition-related expenses.  See reconciliation tables below for full details.

"2009 was a year of strong financial performance and significant strategic importance for Cornerstone," said Craig A. Collard, Cornerstone's Chairman and Chief Executive Officer.  "We achieved over $100 million in annual sales for the first time in 2009.  At the same time, we acquired our two lead specialty products, Curosurf and Factive, as a key part of our strategy to transition our business to focus on strategic specialty products.  We are committed to building a leading specialty pharmaceutical company focused on diseases associated with respiratory disorders.  Importantly, we began 2010 with approximately $19 million in cash and no debt.  We believe that this financial flexibility should allow us to focus on acquiring and developing further specialty products with the goal of generating consistent long term earnings growth."

Fourth Quarter and Full year Financial Results

Net revenue for the fourth quarter of 2009 was $30.8 million, a 48% increase compared to $20.8 million for the fourth quarter of 2008.  Net revenue for the 12 months ended December 31, 2009 was $109.6 million compared to $64.9 million, a 69% increase over the 12 months ended in December 31, 2008.

Curosurf net product sales were $8.3 million for the three months ended December 31, 2009.  The Company acquired an exclusive ten year U.S. license to the Curosurf product rights from Chiesi Farmaceutici S.p.A. (Chiesi) during the third quarter of 2009 and began promoting and selling Curosurf in September 2009.

Our two antibiotics, Factive and Spectracef®, generated combined revenue of $3.6 million for the three months ended December 31, 2009.  During the same period of 2008, Spectracef generated revenues of $5.5 million.  Factive and Spectracef, generated combined revenue of $10.6 million for the 12 months ended December 31, 2009 and Spectracef generated revenues of $7.0 million over the same period in 2008. Factive product rights and related inventory were acquired through an asset purchase agreement with Oscient Pharmaceuticals Corporation on September 9, 2009.  The Company began earning revenues from Factive in September 2009, but did not initiate marketing and promotional activities until October 2009.

Zyflo CR® and Zyflo®, our leukotriene synthesis inhibitor drugs, generated revenues of $4.1 million and $18.0 million for the three and 12 months ended December 31, 2009, respectively.  As noted below, net product sales in 2008 for Zyflo and Zyflo CR do not include sales by Critical Therapeutics prior to the completion of our October 31, 2008 merger.

Our non-strategic products, including our AlleRx® Dose Pack products and our HyoMAX products, comprised 48% of net product sales for the three months ended December 31, 2009, as compared to 69% during the same period of 2008.  Non-strategic products comprised 64% of net product sales for the 12 months ended December 31, 2009, compared to 88% for the same period in 2008.

Gross margin (exclusive of the amortization of product rights) was 70% and 86% for the three months ended December 31, 2009 and 2008, respectively.  Gross margin was 82% and 91% for the 12 months ended December 31, 2009 and 2008, respectively.  The lower gross margins resulted primarily from the Company's intentional change in product mix.  Cornerstone expects gross margins to continue to be in excess of 70% in 2010.

Sales and marketing expenses increased $10.6 million for the 12 months ended December 31, 2009 compared to the 12 months ended December 31, 2008 and $1.8 million for the three months ended December 31, 2009 compared to the same period in 2008.  These increases were primarily attributable to increases in labor and benefits-related costs as a result of the growth of Cornerstone's sales forces, including the addition of our hospital sales force and management team; marketing and promotional spending relating to the launches of Zyflo CR, Factive and Curosurf; and co-promotion expenses relating to Zyflo CR.

General and administrative expenses increased $7.5 million for the 12 months ended December 31, 2009 compared to the 12 months ended December 31, 2008.  This increase was primarily due to increases in labor and benefits-related employee expenses and travel-related expenses; legal and accounting costs related to Cornerstone becoming a public company and costs associated with the Chiesi transaction; FDA regulatory-related fees; and product liability and other insurance related costs.  Costs associated with the Chiesi transaction were $3.3 million, which included $1.5 million of additional stock-based compensation expense due to acceleration of certain stock options and shares of restricted stock and $1.8 million of legal, accounting and related fees.  For the three months ended December 31, 2009, these expenses decreased by $1.2 million compared to the same period in 2008.  This decrease was primarily due to reductions in stock-based compensation expense, regulatory fees, insurance and uncapitalized merger-related expenses in the three months ended December 31, 2009 compared to the same period in 2008.

Research and development expenses increased $0.5 million, or 12%, for the 12 months ended December 31, 2009 compared to the 12 months ended December 31, 2008.  This increase was driven by an increase in expenses related to our product candidate, CRTX 067, and other projects.  For the three months ended December 31, 2009, these expenses decreased by $1.4 million compared to the same period in 2008.  This decrease was primarily due to the write-off of acquired in-process research and development costs of $1.9 million in the fourth quarter of 2008, partially offset by an increase in expenses related to CRTX 067.  Cornerstone expects to continue incurring significant development and commercialization expenses as it seeks to advance the development and seek FDA approval of its product candidates.

Key Financial Metrics

    
    
    
                             Three Months Ended        12 Months Ended
                                December 31,            December 31,
                              2009          2008     2009           2008
    GAAP income (loss) from
     operations             $3,474         $(140) $15,878        $10,628
    Non-GAAP income from
     operations(1)          $7,382          $730  $27,034        $12,711
                            ======          ====  =======        =======
    
    GAAP net income         $2,688        $2,862  $10,203         $8,993
    Non-GAAP net income(2)  $5,220        $3,694  $17,432        $10,984
                            ======        ======  =======        =======
    
    GAAP net income per
     share, diluted          $0.11         $0.29    $0.54          $1.14
    Non-GAAP net income per
     share, diluted(3)       $0.20         $0.34    $0.93          $1.40
                             =====         =====    =====          =====
    
    

(1) Non-GAAP income from operations is a non-GAAP financial measure that excludes stock-based compensation, amortization of product rights and acquisition-related expenses.  See reconciliation tables below for full details.

(2) Non-GAAP net income is a non-GAAP financial measure that excludes stock-based compensation, amortization of product rights and acquisition-related expenses, and the income tax effects of these items. See reconciliation tables below for full details.

(3) Non-GAAP net income per share, diluted is a non-GAAP financial measure that is calculated as non-GAAP net income divided by the diluted weighted-average common shares.  See reconciliation tables below for full details.

2010 Outlook

Cornerstone is reiterating the 2010 revenue guidance it provided in January of this year of in excess of $112 million.  This estimate assumes that revenue contribution from strategic specialty products will increase from less than 40% of net revenues in 2009 to in excess of 75% of net revenues in 2010.  In addition, the Company continues to anticipate achieving income from operations on a GAAP basis of $1.0 million and on a non-GAAP basis of $16.4 million.

Key Financial Metrics

    
    
    
           $million (except per share)             2010
                                                In excess
                                                    of
    Net Revenue                                    $112
    
    GAAP  income from operations                   $1.0
    Non-GAAP income from
     operations(1)                                $16.4
                                                  =====
    
    GAAP net  income                               $0.6
    Non-GAAP net income(2)                        $10.2
                                                  =====
    
    GAAP net income per share, diluted            $0.02
    Non-GAAP net income per share,
     diluted(3)                                   $0.38
                                                  =====
    
    

(1) Non-GAAP income from operations is a non-GAAP financial measure that excludes expected stock-based compensation ( $1.0 million) and amortization of product rights ( $14.4 million).

(2) Non-GAAP net income is a non-GAAP financial measure that excludes expected stock-based compensation ( $1.0 million) and amortization of product rights ( $14.4 million), and the income tax effects of these items totaling $9.6 million.

(3) Non-GAAP net income per share, diluted is a non-GAAP financial measure that is calculated as non-GAAP net income divided by the diluted weighted-average common shares. Based on our current estimates, we have assumed that we will have 26.6 million diluted weighted-average common shares outstanding during 2010.

Conference Call Information

Cornerstone Therapeutics will host a conference call today at 8:30 AM ET to discuss its financial results for the three and 12 months ended December 31, 2009 and to provide an update on its strategy, operations and product development pipeline.  To participate in the live conference call, please dial 888-873-4896 (U.S. callers) or 617-213-8850 (international callers), and provide passcode 43567041.  A live webcast of the call will also be available through the "Investors— Webcasts & Presentations" section of the Company's website at www.crtx.com.  Please allow extra time prior to the webcast to register for the webcast and to download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning today at 11:30 AM ET, by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 97628310.

Use of Non-GAAP Financial Measures

This press release highlights the Company's financial results on both a GAAP and a non-GAAP basis.  The GAAP results include certain costs and charges that are excluded from non-GAAP results.  By publishing the non-GAAP financial measures, management intends to provide investors with additional information to further analyze the Company's performance and underlying trends.  Management evaluates results and makes operating decisions using both GAAP and non-GAAP measures included in this press release.  Non-GAAP results are not prepared in accordance with GAAP, and non-GAAP information should be considered a supplement to, and not a substitute for, financial statements prepared in accordance with GAAP.  Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures to their most directly comparable GAAP measures attached to this press release.

1 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs